Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Actinium Pharmaceuticals Received U.S. Patent Extending Into 2040 And Covers Methods Using Iomab-ACT For Conditioning Patients Prior To The Administration Of Gene-edited Hematopoietic Stem Cell Therapy To Treat Non-malignant Disorders

Author: Benzinga Newsdesk | August 01, 2024 08:15am

Posted In: ATNM